NASDAQ$MMED
MiniMed Group, Inc · Q3 2025 earnings
Q3 2025 earnings ·
Briefing
MiniMed Group reported fiscal Q3 2025 net sales of $790M and a net loss attributable to the company of $119M.
For the three months ended January 23, 2026 (fiscal Q3 2025), net sales were $790 million (+15% YoY) with a net loss attributable to the company of $119 million versus $10 million a year ago. The diabetes technology carve-out from Medtronic completed its March 2026 IPO at $20 per share.
- Net sales $790M (+15% YoY).
- Net loss to company $(119)M.
- IPO completed March 2026.
- Pumps and CGM categories drive mix.
Headline financials
Revenue & EPS history
MiniMed Group, Inc · Revenue · Quarterly
$790M
Revenue by segment
MiniMed Group, Inc · $837M total across 4 segments · Q4 2026
- CGM$420M—50.2%
- Consumables$249M—29.7%
- Pumps$146M—17.4%
- Other$22M—2.6%
Forward guidance
Post-IPO outlook focuses on CGM/pump adoption, Blackstone royalty arrangements, and Italian payback accruals.
Tailwinds
- Strong top-line growth pre-IPO.
- Large addressable diabetes device market.
Headwinds
- GAAP losses and litigation charges.
- Separation and stand-up costs from Medtronic.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
+8.8%
Avg return
Earnings day
+7.1%
Avg return
5 days after
-23.0%
Avg return
30 days after
100%
2 / 2 earnings
Positive
+14.5%
Q4 2026
Best reaction
+3.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +14.5% | +20.2% | — | |
| Q3 2025 | +3.0% | -5.9% | -23.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro